Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions

Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions

Purpose: Neurogenic lower urinary tract dysfunction (NLUTD) is common in patients with neurological lesions in the central nervous system (CNS). Medical treatment usually cannot adequately relieve NLUTD. This study reported the real-life treatment outcome of botulinum toxin A (BoNT-A) for overactive...

Bibliografske podrobnosti
Main Authors:	Yuan-Hong Jiang, Jia-Fong Jhang, Sheng-Fu Chen, Hann-Chorng Kuo
Format:	Article
Jezik:	English
Izdano:	MDPI AG 2024-03-01
Serija:	Toxins
Teme:	lower urinary tract dysfunction overactive bladder dysfunctional voiding neurogenic bladder botulinum toxin A
Online dostop:	https://www.mdpi.com/2072-6651/16/3/123

Podobne knjige/članki

Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life treatment outcome of botulinum toxin A
od: Hann-Chorng Kuo
Izdano: (2024-05-01)

Strategies for Safe Transurethral Injections of Botulinum Toxin into the Bladder Wall
od: Matthias Oelke
Izdano: (2024-06-01)

Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment
od: Agnieszka A. Licow-Kamińska, et al.
Izdano: (2023-12-01)

Efficacy of Urethral Sphincter Botulinum Toxin A Injection in Patients with Spinal Cord Injury with Dysuria: A Retrospective Cohort Study
od: Wan-Ru Yu, et al.
Izdano: (2024-07-01)

Bladder onabotulinum toxin A injections and patients: Office-based vs. operating room setting
od: Daniele Bianchi, et al.
Izdano: (2024-06-01)

Botulinum Toxin Injection for Medically Refractory Neurogenic Bladder in Children: A Systematic Review
od: Shu-Yu Wu, et al.
Izdano: (2021-06-01)

Predictive Factors for the Successful Outcome of Urethral Sphincter Injections of Botulinum Toxin A for Non-Neurogenic Dysfunctional Voiding in Women
od: Chia-Cheng Yang, et al.
Izdano: (2024-09-01)

Does botulinum therapy affect the urine microbiome of patients with neurogenic bladder? Metagenomic sequencing results
od: E. S. Philippova, et al.
Izdano: (2020-10-01)

Efficacy and Safety of Low-Dose Intravesical OnabotulinumtoxinA Injections in Female Patients With Detrusor Overactivity With Detrusor Underactivity
od: Hyun Seok Na, et al.
Izdano: (2024-03-01)

Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome
od: Wan-Ru Yu, et al.
Izdano: (2024-02-01)

First morning voided volume as a valuable tool for evaluating patients with overactive bladder
od: Cheng-Yen Chiang, et al.
Izdano: (2014-09-01)

Challenges and practical considerations in delivering botulinum neurotoxin to adults with congenital neurogenic lower urinary tract dysfunction with history of genitourinary reconstruction
od: Johnny S. Su, et al.
Izdano: (2024-09-01)

Efficacy, Satisfaction, and Compliance: Insights from 15 Years of Botulinum Toxin Use for Female Urgency Urinary Incontinence
od: Margarida Manso, et al.
Izdano: (2024-07-01)

Evaluating the Efficacy and Safety of Botulinum Toxin in Treating Overactive Bladder in the Elderly: A Meta-Analysis with Trial Sequential Analysis of Randomized Controlled Trials
od: Yu-Hsuan Chen, et al.
Izdano: (2024-11-01)

Response to Treatment with Botulinum Neurotoxin A (BoNT-A) in Children and Adolescents with Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis
od: Andrea Panunzio, et al.
Izdano: (2024-10-01)

M-CHOLINOLYTICS IN RHEABILITATION OF CHILDREN WITH VOIDING DISFUNCTION AND URNARY BLADDER HYPERACTIVITY
od: I.V. Kazanskaya, et al.
Izdano: (2006-03-01)

Long-Term Adherence to Onabotulinum Toxin-A Intradetrusor Injections for Neurogenic Dysfunction in Children—A Retrospective Single-Center Evaluation
od: Chiara Pellegrino, et al.
Izdano: (2024-07-01)

Taiwanese Continence Society clinical guidelines for diagnosis and management of neurogenic lower urinary tract dysfunction
od: Hann-Chorng Kuo, et al.
Izdano: (2014-06-01)

Risk factors associated with the severity of overactive bladder among Syrian patients with type 2 diabetes
od: Fater A. Khadour, et al.
Izdano: (2024-07-01)

Real-World Use of Intradetrusor Botulinum Toxin Injections: A Population-Based Study from France
od: Alain Ruffion, et al.
Izdano: (2024-10-01)

Sacral neuromodulation outcomes in the management of lower urinary tract symptoms in multiple sclerosis patients
od: Tyler Trump, et al.
Izdano: (2025-03-01)

Sacral Neuromodulation: Device Improvement and Current Applications in Urology
od: Marco Spilotros, et al.
Izdano: (2024-03-01)

Clinical guidelines of patient-centered bladder management of neurogenic lower urinary tract dysfunction due to chronic spinal cord injury – Part 4: Patient risk, bladder management, and active surveillance
od: Lin-Nei Hsu, et al.
Izdano: (2023-01-01)

Differences in bladder neck angles between female patients with overactive bladders and healthy peers
od: Mehmet Yoldas, et al.
Izdano: (2024-06-01)

Overactive Bladder: Where We Are and Where We Are Going
od: Charan S. Mohan, et al.
Izdano: (2021-09-01)

Association between overactive bladder and female sexual frequency: a cross-sectional analysis of the National Health and nutrition examination survey data
od: Bo Zhang, et al.
Izdano: (2025-02-01)

Botulinum toxin A treatment for lower urinary tract symptoms/benign prostatic hyperplasia
od: Cheng-Ling Lee, et al.
Izdano: (2017-09-01)

Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder
od: Chung-Cheng Wang, et al.
Izdano: (2015-03-01)

Concomitant Botulinum Toxin Injections for Neurogenic Detrusor Overactivity and Spasticity—A Retrospective Analysis of Practice and Safety
od: Arnaud Leilaz, et al.
Izdano: (2024-05-01)

Guidelines for the Treatment of Urinary Incontineence and Overactive Bladder
od: C.F. Heyns, et al.
Izdano: (2002-03-01)

From Toxin to Treatment: A Narrative Review on the Use of Botulinum Toxin for Autonomic Dysfunction
od: Lucas Rempel, et al.
Izdano: (2024-02-01)

Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction
od: Wan-Ru Yu, et al.
Izdano: (2024-01-01)

The Management of Children and Adolescents with Overactive Bladder Refractory to Treatment with Parasacral Transcutaneous Electrical Nerve Stimulation
od: Carlos Eduardo Rocha Macedo, et al.
Izdano: (2025-01-01)

Clinical Experience of the Use of Tolterodine in Patients with Overactive Bladder at Siriraj Hospital
od: Vitaya Titapant, et al.
Izdano: (2020-08-01)

May coexisting overactive-underactive bladder (COUB) be due to muscle fatigue? Data from a single-centre urodynamic database
od: Eleonora Rosato, et al.
Izdano: (2024-03-01)

The role of Kegel exercises in reducing involuntary loss of urine in Overactive Bladder and Mixed Urinary Inconti-nence
od: Lucian Șerbanescu, et al.
Izdano: (2025-01-01)

Overactive bladder ‘symptoms’ or ‘complaints’ in young and elderly patients or healthy volunteers?
od: Alexandra Herrewegh, et al.
Izdano: (2024-03-01)

Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies
od: Ping-Hsuan Yu, et al.
Izdano: (2024-08-01)

Changes in Anxiety-Related Behaviors, Voiding Patterns, and Urinary Bladder Contractile Properties in Male Mice Exposed to Water Avoidance Stress for 1 Day and 28 Days
od: Sarunnuch Sattayachiti, et al.
Izdano: (2024-09-01)

Minimally invasive therapies for older patients with urgency urinary incontinence: Current evidence and recommendations
od: Jacqueline Zillioux, et al.
Izdano: (2025-03-01)